Subscribe

Glossary

Antirheumatic

The word used for any drug that treats a rheumatic disease. It's a category rather than a drug, and it covers things that work in completely different ways.

This word turns up in your notes and inside the name of half the drugs described on this site. It's a category rather than a thing, and the drugs it gathers have almost nothing in common beyond the reason they were prescribed. Knowing that changes which question is useful to ask about any drug with that label.

Quick answerAntirheumatic names any drug used to treat a rheumatic disease, which makes it a category rather than a particular drug. It covers old broad tablets, newer targeted tablets, and injected biologics. One review pooled 88 randomized trials and 31566 people, and every targeted tablet and every biologic in it beat placebo.
Beating placebo is a low bar, and the drugs under this word clear it very differently. In that review the odds ratio for response ranged from 3.05 to 5.61, disease scores improved by between 0.80 and 1.91 points, and disability improved by between 0.21 and 0.34. Look at how wide those ranges are before you read anything reassuring into the category. The word holds together as a category and tells you almost nothing about any single drug inside it. What your notes mean depends entirely on the drug name that follows the word, so read that rather than the category itself.

What the word means

Antirheumatic means any drug used to treat a rheumatic disease, and that's the whole definition. It describes a job rather than a kind of drug, which is an unusual thing for a medical word to do, and it's the reason the word turns up in your notes so often without telling you much. A shelf label is close to what it is, since the shelf holds several families of drug that resemble each other in nothing except what they get prescribed for.

You'll meet the word inside longer names, and disease-modifying antirheumatic drug is much the most common of those, usually shortened to DMARD. Those first two extra words hold nearly all of the meaning. Strip them away and what's left describes the shelf rather than anything resting on it.

Where the word stops helping

The risks and the choices live at the level of the drug rather than at the level of the category, and one review makes that concrete. It pooled 21 trials and 8361 people with early rheumatoid arthritis. Adalimumab with methotrexate led on remission, at an odds ratio of 2.90 from 1.94 to 4.33, and tocilizumab with methotrexate led on the strictest response measure, at 4.41 from 2.29 to 8.49.

That review found just one safety signal across everything it studied. Tocilizumab with methotrexate showed more side effects, at an odds ratio of 5.11 from 2.03 to 12.86, and nothing of the sort turned up for any of the others. One signal, one combination, and dozens of drugs under the word.

So a sentence about antirheumatic drugs and side effects would be close to meaningless as written. The signal belonged to one combination and the word covers dozens of drugs, so a sentence pitched at the category would be both true and useless. Read the drug, not the category, because that's where every answer you want is kept.

Pregnancy

One study looked at pregnancy outcomes in women taking these drugs, and both what it covered and what it left out are worth knowing. It compared 921 pregnancies in women with psoriatic arthritis against 9210 matched pregnancies in women without it. The women with the condition differed at the start, being more often obese, more often smokers, and more often living with high blood pressure or diabetes.

Two of the outcomes came out raised, and both are worth reading with the study's limits in mind. Preterm birth came in at an adjusted odds ratio of 1.69, from 1.27 to 2.24, and caesarean delivery at 1.77, from 1.43 to 2.20, for a planned one. An emergency caesarean came in at 1.42, from 1.10 to 1.84. That study also found the risks differed by whether treatment was given, by when it was given, and by which treatment it was.

This page can't take that any further and it shouldn't try. Pregnancy decisions about these drugs belong with your own team, and ideally before conception if there's any choice about the timing. One more thing about that study is worth noting, which is that it covered psoriatic arthritis only, so a different diagnosis means those numbers describe somebody else.

Common misconceptions.

Myth. Antirheumatic is the name of a kind of drug.

Reality. It's the name of a job rather than the name of a kind, which is why three quite different things are grouped under it. There are old tablets that damp the whole immune system, newer tablets that block one signal inside a cell, and injected proteins that block one signal outside it. What those three share is the reason they get prescribed.

Myth. If two drugs are both antirheumatic they're interchangeable.

Reality. They aren't, and the review that put them all above placebo also spread them out. Across 88 trials and 31566 people, the odds ratios for response ranged from 3.05 all the way to 5.61. Tocilizumab, certolizumab pegol, and upadacitinib ranked relatively well across three outcomes, and tocilizumab beat the other active drugs on disease score by between 0.49 and 1.11 points.

Myth. A higher dose of these drugs works better.

Reality. Not for one family of them, on the evidence in that review. Raising a targeted tablet above the lower recommended level gave no extra benefit on response, no extra benefit on disease score, and no extra benefit on disability. That's a finding about those particular drugs rather than a rule about medicine, and your own dose stays a decision for your team.

Myth. The word tells me something about side effects.

Reality. It doesn't, because the risks belong to the drug rather than to the category. One review pooled 21 trials and 8361 people and found a single safety signal across everything it studied, and that signal belonged to one particular combination. It says nothing at all about the other drugs the same word covers.

Myth. Antirheumatic drugs are all taken as tablets.

Reality. Some are and some aren't, and the split follows what the drug is made of. The older ones are tablets and so are the newer targeted ones, but biologics are proteins grown in living cells rather than chemicals built in a factory. They're injected under the skin or given by a drip, because a protein that size wouldn't survive being swallowed.

Related terms.

References.

  1. Weng C; Xue L; Wang Q et al. Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis. Ther Adv Musculoskelet Dis. 2021;13:1759720X21999564. 10.1177/1759720X21999564Systematic review and network meta-analysis of randomised controlled trials to April 2020 comparing three JAK inhibitors and eight biologic disease-modifying drugs against placebo or conventional synthetic drugs
  2. Remaeus K; Johansson K; Granath F et al. Pregnancy Outcomes in Women With Psoriatic Arthritis in Relation to Presence and Timing of Antirheumatic Treatment. Arthritis Rheumatol. 2022;74:486-495. 10.1002/art.41985Swedish nationwide registry-based cohort study of 921 pregnancies in women with psoriatic arthritis and 9210 pregnancies without
  3. Xu H; Li C; Ding R et al. Efficacy and safety of non-conventional synthetic disease-modifying antirheumatic drugs in early active rheumatoid arthritis: a network meta-analysis. BMC Rheumatol. 2025;10:5. 10.1186/s41927-025-00603-xSystematic review and network meta-analysis of randomised controlled trials to February 2025
  4. Choy E; Freemantle N; Proudfoot C et al. Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses. RMD Open. 2019;5:e000798. 10.1136/rmdopen-2018-000798Systematic literature review and network meta-analyses of 24-week efficacy and safety outcomes
  5. Decarriere G; Barnetche T; Combe B et al. Most Appropriate Conventional Disease-Modifying Antirheumatic Drug to Combine With Different Advanced Therapies in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis. Arthritis Care Res (Hoboken). 2021;73:873-884. 10.1002/acr.24195Systematic literature review with meta-analysis comparing methotrexate against other conventional synthetic disease-modifying drugs when combined with advanced therapies in rheumatoid arthritis

Free download

The First Changes to Make.

The same handout I hand my own patients: the specific food and daily-exposure changes worth making first, no guesswork required.

We'll email you the list and keep your address so we can send you something occasionally. We won't sell it or pass it on, and you can unsubscribe from any email. How we handle it.

No spam · Unsubscribe any time

This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.